Sirolimus reduces polycystic liver volume in ADPKD patients. - Wikidata - wikimedia - TriplyDB

Sirolimus reduces polycystic liver volume in ADPKD patients.

Sirolimus reduces polycystic liver volume in ADPKD patients.

http://www.wikidata.org/entity/Q36667245

about

Interventions for preventing the progression of autosomal dominant polycystic kidney disease Interventions for preventing the progression of autosomal dominant polycystic kidney disease Autosomal dominant polycystic kidney disease: the last 3 years Polycystic liver diseases: advanced insights into the molecular mechanisms PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease Advances in the pathogenesis and treatment of polycystic kidney disease Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.Polycystic kidney disease.Isolated polycystic liver disease.ALADIN: wish granted in inherited polycystic kidney disease?Novel targets for the treatment of autosomal dominant polycystic kidney disease.Regulation of renal tubular glucose reabsorption by Akt2/PKBβ Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.Sirolimus therapy to halt the progression of ADPKD.Treatment strategies and clinical trial design in ADPKD microRNA biomarkers in cystic diseases.An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study.ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease.ADPKD: Prototype of Cardiorenal Syndrome Type 4 Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks.Polycystic liver disease.Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease.Medical therapy for polycystic liver disease.Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease Volume regression of native polycystic kidneys after renal transplantation.Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside.SSAT/AHPBA joint symposium on evaluation and treatment of benign liver lesions.Current insights into renal ciliopathies: what can genetics teach us?Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?Cholangiociliopathies: genetics, molecular mechanisms and potential therapies Advances in management of polycystic liver disease.Emerging evidence of a link between the polycystins and the mTOR pathways.Polycystic liver disease presenting as pruritus.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Systematic review: the pathophysiology and management of polycystic liver disease.

P2860

Q24186484-7DD4E7FF-37E4-4C6E-A606-486433E4D514 Q24201920-556CD06D-A1EF-4850-819A-EC180CEB7CA9 Q24656249-331F9A4F-3809-40E5-A9D3-0C44EA153845 Q27001174-4EBA2808-7118-4F8B-9682-7538070A7132 Q28742454-DE802439-AABA-4E2B-B8D2-A886294581F2 Q33646379-35DF9576-41DC-400B-A7F4-1233B62C4E98 Q33702386-377A04DB-70C5-4684-87FB-595700A6F3C7 Q33709685-6B591B69-469C-48D3-BF94-D01F457EA311 Q33723830-BF630238-0143-4376-ADE4-715267267A65 Q33745445-8C934BDC-09E1-47D2-9727-7E8E03B2D199 Q33816594-9EC10BCC-033E-445C-B1A1-6729A90343AC Q33976316-1B3E3228-7A2C-4355-BC04-FF22ADA39CE1 Q33979298-F2A0B673-5440-47F7-A02A-2BDFC50DAA8E Q33979376-AF187B3F-4606-49BA-ABFF-9118AA1A8CE7 Q34024396-3A76D8E9-0FF2-46E7-80D9-2C70A7F8D5BA Q34049572-33061D28-31A4-4CE1-9186-E801F029FF54 Q34074513-D9774DB1-E783-4698-8A46-27917914AB55 Q34091331-35D09B22-68DD-4C2C-921E-8479D96E5BA1 Q34185922-F50C899A-8012-4F80-B80F-2B250F8F300C Q34399971-A5043AA9-8ECD-4E41-803F-FB81685E5AC7 Q34475383-5CDF14FA-0403-4F16-A9B7-B79BBF79E878 Q34475590-41FC5F75-59F1-4E1C-B74F-E22E6A057A42 Q34658323-08837741-C725-438B-BA13-D0108363A5E3 Q34933719-1DE6051E-ACF6-42EF-89BD-9E4D039DA7F0 Q35619287-75214975-9D2C-477D-879A-EF29F5F86C00 Q35655072-A2B3E84E-1B28-4180-AE30-06D18959B9D7 Q35873958-0528464F-8B6E-4B29-9461-C0B1728A5288 Q35917458-C4479059-2DB2-49C5-A895-FD50E5303187 Q35964504-0BAC01D4-165E-4CA1-817A-81E86DBDF0E3 Q36435509-9043C5F0-8A06-4ABF-8FC1-883CCA78128D Q36471777-EA863397-D763-436F-BE2C-B0007F355C9B Q36773151-A8EAA4B7-EF23-4124-AC5F-3D4FCAE0B453 Q36780455-E01495F3-900A-43A0-B99D-B12930C92C2D Q36968695-4B25C860-BD7C-4656-BE2A-8DE218BEF097 Q37317821-1303A2F8-B571-4760-B5EE-7103C6290694 Q37345965-2D3ACE3B-D956-4533-9325-53085A362022 Q37432510-5E1E7E92-C908-4166-ADF6-2E347634DD63 Q37647738-8C5209A3-F2CB-46B7-9A7F-8EF7C60A4120 Q37760379-2D3CBEA0-A5D0-4A6D-A89A-A3B9F5772ED7 Q37905881-ABD35EF1-6594-49F6-A18F-63A405D1DD5B

P2860

Sirolimus reduces polycystic liver volume in ADPKD patients.

http://www.wikidata.org/entity/Q36667245

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Sirolimus reduces polycystic liver volume in ADPKD patients.

@ast

Sirolimus reduces polycystic liver volume in ADPKD patients.

@en

type

label

Sirolimus reduces polycystic liver volume in ADPKD patients.

@ast

Sirolimus reduces polycystic liver volume in ADPKD patients.

@en

prefLabel

Sirolimus reduces polycystic liver volume in ADPKD patients.

@ast

Sirolimus reduces polycystic liver volume in ADPKD patients.

@en

P1433

Q36667245-FF8470DE-2230-4E6D-9F14-B5CCC25DB4DC

P1476

Q36667245-E18756CE-AB91-46AB-A344-C0EA514CFE23

P2093

Q36667245-255861B0-2D40-426E-8335-10D13FC3D5A2

Q36667245-71BFE716-716E-420E-997D-525200628364

Q36667245-956BCE57-1A55-4D96-9D96-F775191C297E

Q36667245-A1D5D4E1-7EA2-4C3D-BCD4-2DC109B83FFA

Q36667245-C825ED97-92C2-4B73-993B-7E32FDDF3913

Q36667245-F8D3F604-E9BF-490F-9929-8A79C54BF0D5

Q36667245-FCBDABEA-E7DD-468F-826E-3F949F485E49

P2860

Q36667245-0A82D979-A82F-43A7-8660-6A3C8A0B3263

Q36667245-1D13B2B8-6E95-4DDB-AE77-DB7CCB528545

Q36667245-1F2415F6-E840-45FB-BAA3-B33612033363

Q36667245-26FEFF82-63F5-4B0F-857C-14D323FA5AF8

Q36667245-2A5D93B7-6AD1-46FA-8BFA-FE20234622B5

Q36667245-2F64BF2F-C796-4633-8DB9-D49AC5D5C4B7

Q36667245-2FCC5754-50C1-4670-B7F7-47BD80FF5C38

Q36667245-3D4174C4-1BB1-47B4-88F7-600C133BF7A3

Q36667245-45756BBA-1456-4E2C-8EF5-416911031EA6

Q36667245-481C3BDF-1836-40F2-8A34-D9162F350342

P304

Q36667245-87BA3869-B02C-4392-AAAF-01DB710C1B0C

P31

Q36667245-A87AB8F6-6E5F-491B-9997-B80C22E91036

P356

Q36667245-68F890F6-7D72-4109-9BFE-D24C519FF00C

P433

Q36667245-3B9724EC-C69A-4C94-8144-5DC1810FBB83

P478

Q36667245-42E68E15-C4C1-42D3-B2BC-879342E16E6D

P577

Q36667245-1F250F90-777D-4527-A5D9-4BF9A7DBA8C8

P698

Q36667245-BB4A13E2-C1C7-4B5F-9C40-FE6CFD33ACEB

P932

Q36667245-9D06EB7C-CD00-4F79-843D-C2E35ABD1B27

P356

P1433

Journal of the American Society of Nephrology

P1476

Sirolimus reduces polycystic liver volume in ADPKD patients.

@en

P2093

Bernard F King

http://www.w3.org/2001/XMLSchema#string

Fernando G Cosio

http://www.w3.org/2001/XMLSchema#string

Hui Du

http://www.w3.org/2001/XMLSchema#string

Patrick G Dean

http://www.w3.org/2001/XMLSchema#string

Qi Qian

http://www.w3.org/2001/XMLSchema#string

Sumedha Kumar

http://www.w3.org/2001/XMLSchema#string

Vicente E Torres

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery

Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries

Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase

P304

631-638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2007050626

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18199797

http://www.w3.org/2001/XMLSchema#string

P932

2391057

http://www.w3.org/2001/XMLSchema#string